Opsumit (macitentan) failed to improve the cardiac function of people with pulmonary hypertension stemming from a heart problem, a…
Articles by Alice Melão, MSc
Bellerophon Therapeutics has enrolled more than half the 188 patients it is seeking for its ongoing Phase 3 clinical trial…
Results of a Phase 1 clinical trial of Liquidia Technologies’ powder formulation of treprostinil for pulmonary hypertension were promising enough…
Interim data collected from a Japanese clinical setting demonstrates the post-marketing efficacy and safety of Volibris (Letairis, ambrisentan) for the…
Ubenimex, an oral dual-inhibitor developed by Eiger BioPharmaceuticals, has failed to demonstrate its effectiveness to treat pulmonary arterial hypertension…
A group of clinician-researchers with expertise in the field of cardiovascular and pulmonary diseases propose in a commentary that guidelines…
Tracleer (bosentan) may be of significant benefit to people with borderline or less severe pulmonary hypertension (PH)…
SteadyMed Therapeutics will do more testing to answer American regulators’ questions about the safety and effectiveness of its PatchPump pulmonary…
Anti-clotting agents can prevent pulmonary hypertension patients’ blood vessels from being blocked, but managing the agents can be challenging, a…
Adempas (riociguat) can be a safe way to treat children with severe pulmonary arterial hypertension (PAH) who don’t…
Nearly one in every two people with advanced lung cancer also have pulmonary arterial hypertension, a study published in the journal…
Patients with elevated pulmonary arterial pressure, but not high enough to be diagnosed with pulmonary hypertension (PH), have a…